Floatz Rating
B62/100
Confidence
Indicative
Sponsor
The Lymphoma Academic Research Organisation
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06558604CT.gov Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma | — | Recruiting | — | — | — |
NCT06522386CT.gov GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06496308CT.gov Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | — | Recruiting | — | — | — |
NCT06324994CT.gov Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | — | Not Yet Recruiting | — | — | — |
NCT05910801CT.gov Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT05951959CT.gov A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05665530CT.gov A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | — | Completed | — | — | — |
NCT05864742CT.gov Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05861050CT.gov Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT05529069CT.gov Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients | — | Recruiting | — | — | — |
Show 23 more trialsShow fewer
NCT04939272CT.gov Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05025423CT.gov Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT05107856CT.gov PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | — | Terminated | — | — | — |
NCT04802590CT.gov Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04599634CT.gov Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | — | Completed | — | — | — |
NCT04990778CT.gov Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT04855695CT.gov Avo In R/R And Previously Untreated MCL | — | Recruiting | — | — | — |
NCT04659044CT.gov Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT04419389CT.gov APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | — | Terminated | — | — | — |
NCT04477486CT.gov Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03834688CT.gov Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age | — | Completed | — | — | — |
NCT03946878CT.gov Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03856112CT.gov Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03710772CT.gov Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03872180CT.gov Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03740529CT.gov A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | — | Completed | — | — | — |
NCT03523975CT.gov Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT03567876CT.gov Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL | — | Completed | — | — | — |
NCT03547115CT.gov A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | — | Terminated | — | — | — |
NCT03295240CT.gov The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT03112174CT.gov Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) | — | Completed | — | — | — |
NCT02471391CT.gov ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) | — | Unknown | — | — | — |
NCT02419560CT.gov Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Venetoclax (this asset) | The Lymphoma Academic Research Organisation | P3 | B · 62 |
| Etoposide | Ruijin Hospital | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BBB |
| Busulfanum | City of Hope Medical Center | P2 | BBB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Romidepsin | City of Hope Medical Center | P2 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for Venetoclax
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P4 | BB · 70 |
| Acute Myeloid Leukemia | — | P4 | BB · 69 |
| Chronic Myelomonocytic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Venetoclax in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/venetoclax-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →